Secondary metabolites in tuberculosis: the 2010 review

Why Did the Review Focus on Secondary Metabolites?

The authors framed the search for new antituberculosis agents around the problem of drug resistance and the limitations of lengthy treatment regimens. They argued that natural products offered chemically diverse compounds that could be screened for activity against mycobacteria. The review therefore gathered evidence from medicinal plants, microorganisms and marine organisms rather than concentrating on a single botanical source.

A compound with laboratory antimycobacterial activity must undergo further evaluation before it can be considered for therapeutic development. An active molecule must still be evaluated for selectivity, toxicity, stability and its ability to reach the relevant infection sites. Chemical diversity makes screening worthwhile, but discovery is only the earliest stage of a much longer development process.

Secondary metabolites are compounds that are not primarily required for basic growth and reproduction but can perform ecological functions such as defence. In the review, their importance was practical: structurally different natural compounds had already produced measurable inhibition in laboratory antimycobacterial assays.

How Broad Was the Plant Evidence Reviewed?

Kumar and colleagues reported approximately 17,500 plant species in India and stated that about 365 had been verified for antimycobacterial activity at the time of their review. Of those 365 species, 255 — about 70% — were described as showing antimycobacterial activity. These figures summarize the literature available to the authors in 2010 and do not indicate clinical effectiveness in people.

The 365 investigated species were not a random sample of India's flora, so the reported proportion of active species cannot be generalized to all plants. Screening methods, extraction solvents and tested organisms can affect which materials appear active. Consequently, the percentage should not be extrapolated to untested species or used to estimate the likelihood that a traditional preparation works in patients.

Screening results are not clinical outcomes

The paper repeatedly draws on minimum inhibitory concentration (MIC) values and other in vitro measurements to describe the antimycobacterial activity of natural compounds. These laboratory results can identify promising plant extracts, isolated metabolites and chemical structures for further investigation. However, the ability to inhibit bacterial growth under controlled experimental conditions does not establish that a substance can safely or effectively treat tuberculosis in humans. Differences in bacterial strains, assay methods and tested concentrations can also influence the reported results and limit comparisons between compounds. Additional studies are needed to determine whether active substances remain effective in more complex biological systems and whether they produce harmful effects on host cells. The authors concluded that promising candidates required further testing against pathogenic mycobacterial strains and evaluation in vivo before their therapeutic potential could be assessed.

Which Classes of Natural Compounds Were Discussed?

The review grouped antimycobacterial natural products into several chemical classes based on their chemical structures and biological origins. Alkaloids received substantial attention because several compounds within this group had demonstrated measurable activity against mycobacteria in laboratory experiments. Flavonoids and related phenolic compounds, including coumarins and chalcones, were also discussed alongside terpenoids, steroids, saponins and peptides. These substances originated from diverse biological sources, including terrestrial plants, fungi, bacteria and marine organisms. Their structural differences provided multiple starting points for investigating potential antimycobacterial agents, although activity varied considerably between individual compounds. The review also highlighted that substances belonging to the same chemical class could produce different experimental results depending on their molecular characteristics and testing conditions.

Examples of compound classes and reported activity

Selected compounds demonstrate differences in antimycobacterial activity across chemical classes and biological sources. Their reported minimum inhibitory concentration (MIC) values indicate the concentrations required to inhibit visible microbial growth under specific laboratory conditions. Some isolated metabolites showed activity at relatively low concentrations, while others required substantially higher amounts to produce measurable inhibition. These differences may reflect variations in chemical structure, bacterial susceptibility and experimental methods rather than a consistent advantage associated with any particular compound class. Consequently, the reported values illustrate the diversity of natural-product research and the range of observed laboratory activities, not a ranking of potential tuberculosis treatments. Further pharmacological and biological testing is necessary to determine whether promising compounds have suitable safety profiles and therapeutic properties.

Table 1. Examples of Compound Classes and Reported Activity

What Did the Review Say About Alkaloids?

Alkaloids were presented as one of the major natural-product groups with antimycobacterial activity. The review noted testing of 23 naturally occurring alkaloids and analogues and discussed carbazole, indole and benzoxazole-related compounds from plant and marine sources. It also cited activity against several Mycobacterium species, showing that the underlying literature was not limited to M. tuberculosis alone.

Examples in the review include cryptolepine, echinuline, pseudopteroxazole-related compounds and sanguinarine. Reported MIC values varied substantially, reinforcing that a chemical class cannot be treated as uniformly active.

How Were Flavonoids and Related Compounds Presented?

The authors grouped flavonoids with coumarins, chromones and chalcones and described several structural subclasses of flavonoids. Their examples included ostruthin and licochalcone A, both reported with measurable antimycobacterial activity in cited laboratory studies. The review also connected some plant extracts with traditional use for cough or tuberculosis, but traditional use and laboratory inhibition were not equivalent forms of evidence.

Why chemical structure mattered

Structural diversity offered multiple potential starting points for antimycobacterial drug discovery. Later research has continued to investigate plant phenolics and other secondary metabolites as potential antimycobacterial compounds, while emphasizing the need for pharmacological validation beyond initial screening.

What Role Did Terpenoids, Steroids and Saponins Play?

Terpenoids were another major group. The authors cited research on 118 synthetic and natural plant terpenoids with moderate to high antimycobacterial activity and discussed sources including Sapium indicum, Pseudopterogorgia elisabethae and Xanthocyparis nootkatensis.

Steroidal and saponin examples included compounds associated with Morinda citrifolia, Physalis angulata, Colubrina retusa and marine organisms. Reported MIC values again varied widely, which is important because a promising laboratory value for one compound cannot be generalized to the whole class.

Why Were Peptides and Marine Products Included?

The review did not restrict natural-product research to plants. Cyclodepsipeptides from fungi and compounds from marine organisms were included because several had shown laboratory antimycobacterial activity. For the fungal peptides discussed, the authors reported MIC values ranging from about 1.56 to 25 µg/ml.

The compounds examined originated from plants, fungi, bacteria and marine organisms, extending the investigation beyond herbal preparations. The paper therefore treated natural-product research as a discovery pipeline rather than a synonym for herbal medicine.

What About Traditional Remedies Listed in the Review?

A separate table in the paper listed traditional or home-use substances such as barberry, garlic, licorice-root tea, mint preparations, pineapple juice, ginseng and propolis. These entries reflect claims and traditional uses reported by the review authors; they should not be interpreted as evidence that these remedies cure tuberculosis.

Traditional medicinal use, laboratory activity and demonstrated clinical effectiveness represent separate levels of evidence. A plant preparation may contain numerous compounds, whereas laboratory studies often examine isolated substances under contrnt levels of evidence.

How Should MIC Values Be Interpreted?

Minimum inhibitory concentration is a laboratory measure of the concentration required to inhibit visible microbial growth under defined conditions. In the review, MIC values were used to compare candidate compounds across different natural sources. Lower reported values can indicate stronger activity within a particular assay, but comparisons are limited when organisms, methods and experimental conditions differ.

MIC values also depend on whether investigators test a purified substance or a complex extract. A concentration reported for one assay cannot automatically be compared with a value obtained under another protocol. Even when a purified compound inhibits bacterial growth in a laboratory, its absorption, metabolism and potential toxicity remain separate questions.

Selected activity values reported by Kumar and colleagues

The reported MIC values span a broad range. Antimycobacterial activity varied considerably, including among compounds belonging to the same broad chemical class.

Table 2. Selected Compounds and Their Reported MIC Values

What Were the Review’s Main Limitations?

The paper was a narrative review rather than a systematic review with a documented search strategy, predefined eligibility criteria or formal risk-of-bias assessment. It combined evidence from different Mycobacterium species, assay systems, extracts and isolated compounds, making direct comparison difficult.

Another limitation is the absence of a consistent framework for comparing the strength of evidence across studies. Differences in assay design, bacterial strains and reporting detail can create apparent contrasts that are not biological differences. Confirmatory testing under standardized conditions would be needed before selecting candidates for more advanced development.

Some sections also presented traditional remedies alongside experimental antimycobacterial findings. The authors themselves acknowledged a central evidence gap: many investigations relied on in vitro tests, including studies using non-pathogenic or saprophytic mycobacteria, and promising leads required further work with pathogenic strains and in vivo models.

Why Does the 2010 Review Still Matter?

The 2010 review documents the natural-product compounds investigated as potential antimycobacterial agents at the time. It covers plant alkaloids and terpenoids alongside fungal peptides and marine metabolites, demonstrating the diversity of biologicerial activity around 2010, from plant alkaloids and terpenoids to fungal peptides and marine metabolites.

Research priorities in natural-product drug discovery have changed as new experimental methods and evidence have become available. The 2010 review documents which natural sources and chemical families were being investigated at that time, without demt every lead progressed toward a medicine. Reading the paper alongside subsequent experimental and clinical work helps distinguish enduring scientific questions from preliminary claims.

At the same time, laboratory inhibition and traditional use do not establish clinical benefit. The reported laboratory findings identify potential research candidates but do not establish clinical effectiveness against tuberculosis. 

Practical takeaway: Secondary metabolites offered chemically diverse starting points for tuberculosis drug discovery. However, antimycobacterial activity observed in laboratory assays does not establish that a compound is safe or effective for treating tuberculosis in humans. Further pharmacological, preclinical and clinical evaluation is necessary before promising compounds can be considered therapeutic options.

Frequently asked questions

Eleanor Hayes — author

Eleanor Hayes writes with an editorial focus on research methodology and study design, including experimental and observational studies, controls, sampling, measurement and the methodological choices that shape scientific conclusions. At CAB Direct, Eleanor co...